AbbVie (ABBV) Stock Price, News & Analysis

Company Overview

AbbVie Inc. (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta. Through its Allergan aesthetics business, AbbVie also offers Botox Cosmetic, dermal fillers and other aesthetic treatments. The company’s earlier flagship product, Humira, was used to treat several inflammatory conditions and was one of the world’s leading pharmaceutical products before biosimilar competition began.

AbbVie became an independent company in 2013 after being separated from Abbott Laboratories. Its acquisition of Allergan, completed in 2020, expanded its presence in medical aesthetics, eye care and other specialty markets. AbbVie is headquartered in North Chicago, Illinois, and is led by Chief Executive Officer Robert A. Michael.

Key Stats

• Today's Range: $283.12 to $287.32
• 50-Day Range: $248.75 to $288.66
• 52-Week Range: $190.75 to $291.40
• Volume: 3.27 million shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $279.86
• Consensus Rating: Moderate Buy

AbbVie Stock Analysis - MarketRank™

AbbVie scored higher than 85% of companies evaluated by MarketBeat, and ranked 65th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

AbbVie has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 1 strong buy rating, 23 buy ratings, 6 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for AbbVie is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

AbbVie has been the subject of 21 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 15.22%

Earnings Growth

Earnings for AbbVie are expected to grow by 15.22% in the coming year, from $13.93 to $16.05 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AbbVie is 80.99, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 27.08.

Price to Earnings Ratio vs. Sector

The P/E ratio of AbbVie is 80.99, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.59.

Price to Earnings Growth Ratio

AbbVie has a PEG Ratio of 1.30. PEG Ratios above 1 indicate that a company could be overvalued.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.88% of the float of AbbVie has been sold short.

Short Interest Ratio / Days to Cover

AbbVie has a short interest ratio ("days to cover") of 2.72, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in AbbVie has recently decreased by 4.29%, indicating that investor sentiment is improving.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Yield

AbbVie pays a meaningful dividend of 2.42%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

AbbVie has been increasing its dividend for 53 years.

Dividend Coverage

The dividend payout ratio of AbbVie is 195.48%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, AbbVie will have a dividend payout ratio of 43.12% next year. This indicates that AbbVie will be able to sustain or increase its dividend.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: 0.88

News Sentiment

AbbVie has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 92 news articles for AbbVie this week, compared to 9 articles on an average week.

Search Interest

86 people have searched for ABBV on MarketBeat in the last 30 days. This is an increase of 39% compared to the previous 30 days.

MarketBeat Follows

91 people have added AbbVie to their MarketBeat watchlist in the last 30 days. This is an increase of 184% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, AbbVie insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,177,500.00 in company stock.

Percentage Held by Insiders

0.06% of the stock of AbbVie is held by insiders.

Percentage Held by Institutions

70.23% of the stock of AbbVie is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 8/14 Dividend: 7/15/2026
• Ex-Dividend for 8/14 Dividend: 7/15/2026
• Last Earnings: 7/31/2026
• Dividend Payable: 8/14/2026
• Record date for 11/16 Dividend: 10/15/2026
• Ex-Dividend for 11/16 Dividend: 10/15/2026
• Today: 10/27/2026
• Next Earnings (Estimated): 10/30/2026
• Dividend Payable: 11/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSE:ABBV
• CIK: 1551152
• Web: www.abbvie.com
• Phone: (847) 932-7900
• Fax: 302-655-5049
• Employees: 57,000
• Year Founded: 2013

Price Target and Rating

• Average Price Target for AbbVie: $279.86
• High Price Target: $325.00
• Low Price Target: $225.00
• Potential Upside/Downside: -2.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.83
• Research Coverage: 30 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: 1,765,733,000
• Market Cap: N/A
• Optionable: Optionable
• Beta: N/A